The World Health Organization (WHO) defines walking as "moving along a surface on foot, step by step, so that one foot is always on the ground, such as when strolling, sauntering, walking forwards, backwards, or sideways. integrates walking speed and the need for assistive devices. 7 The DGI, mentioned above, incorporates walking a short distance on level ground at comfortable speed, climbing steps, and a series of tests that challenge the patient's dynamic balance. While walking speed and walking distance have been used for decades as indicators of disease progression, other aspects of gait disturbance are not routinely assessed, and the impact of walking limitations on the daily activities and quality of life of patients is not fully understood.
assessments of activity can be obtained via pedometers, accelerometers, and the use of global positioning system (GPS) odometry. While these devices allow measurement of performance in the patient's environment, and over longer periods of time, compared with the short tests used in the office setting, they do not provide detailed information on gait.
More recently, self-report measures such as the MS Walking Scale-12 (MSWS-12) have been validated, allowing integration of the patient's perception of walking performance (and limitations) into outcome measurement. 9 The MSWS-12 has been used in clinical trials of fampridine-SR (see below).
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Improving Ambulation
Gait Disorders in Multiple Sclerosis
Ambulation limitations are reported by up to 75% of PwMS. 11 The consequences of limited ambulation include decreased ability to perform activities of daily life, reduced quality of life, and medical complications. For example, the high prevalence of osteoporosis in
PwMS has been mostly attributed to decreased mobility, 12 and the combination of osteoporosis and increased risk of falling accounts for a higher incidence of fractures in MS. 13 Therefore, there is a strong incentive to enhance ambulation in PwMS. Specific gait changes observed in PwMS include decreased gait speed, decreased step/stride length, decreased cadence, increased double support time, and increased variability of gait. 14, 15 Quantitative gait analysis detects abnormal gait patterns early in the course of the disease, even in the absence of objective functional limitations. 16 There is an increasing body of evidence regarding the effects of various interventions on ambulation in MS.
Disease-modifying Therapies for Multiple Sclerosis
Treatments for MS can have an impact on walking through the reduction of inflammation and axonal damage. Glucocorticosteroids can hasten recovery from exacerbations of MS, although they may not make a difference in long-term outcome. 17 Disease-modifying therapies (DMTs) may slow the accumulation of disability, in part through a reduction in the frequency of exacerbations, which have been shown to constitute the main source of accrual of disability in relapsing MS. 18 However, when a chronic limitation of walking performance is present, the use of DMTs is not generally expected to lead to a sustained improvement of function.
Rehabilitation
Rehabilitative interventions, particularly physical therapy, are usually the first line of defense when attempting to improve ambulation. 19 In an expert opinion paper, the National Multiple Sclerosis Society Recently, an active orthosis designed to compensate for hip flexor Although there was a significant gain in walking speed, walking distance, and EDSS score after robot-assisted training, there was no statistically significant difference with bodyweight-supported training. 31 Another study showed no significant difference in the effect of robot-assisted gait training versus conventional gait training in 35
MS patients receiving inpatient rehabilitation. 32 Virtual reality improved walking speed and stride length in a study of 16 MS patients with ataxic gait. 33 
Symptom Management
Various symptomatic therapies may have an impact on ambulation in
PwMS. We will focus only on treatments for spasticity and fatigue.
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Fatigue is experienced by most PwMS, is often reported as one of their top complaints, and is a predictor of disability independent of other neurological impairments. [34] [35] [36] Fatigue has been defined as "a subjective lack of physical and/or mental energy which is perceived by the individual or care-giver as interfering with usual and desired activities." 37 The pathophysiology of fatigue is not completely elucidated. 39 Medications commonly used to treat fatigue in MS, such as amantadine and modafinil, have not been shown to improve gait performance. Conversely, fampridine (see below) has a beneficial effect on gait performance, but not on patientreported fatigue. 40 A study of aerobic exercise on treadmill in 16 MS patients showed improvements in walking speed and walking endurance, but not in fatigue. 41 
Spasticity Management
Spasticity, defined as a velocity-dependent increase in stretch reflex, 42 is frequently experienced by PwMS, and has a significant impact on their quality of life. 43 Clinical practice guidelines for the management of spasticity in MS were published by the CMSC and Paralyzed
Veterans of America. 44 Baclofen and Tizanidine are the two most frequently used oral antispasticity agents used in MS. Although these medications have demonstrated efficacy on spasticity-related symptoms in placebo-controlled clinical trials, there are no conclusive data on their functional effects. 45 The same applies to botulinum toxin therapy, which is used for the treatment of focal spasticity in MS and other disorders (although it is not approved for this indication by the FDA): the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (AAN) has recently issued a report based on an extensive review of the literature on botulinum toxin therapy for spasticity, which concluded that "Class I placebocontrolled studies have so far failed to demonstrate gains in walking speed." 46 There is increasing interest in using intrathecal baclofen (ITB) therapy to treat severe spasticity in ambulatory patients with MS.
Sadiq et al. published a case series including 27 patients with MS and
observed no significant loss of walking ability with ITB, but did not report a significant improvement of gait performance. 47 Preliminary results from a prospective uncontrolled study of ITB in ambulatory MS patients showed an improvement of gait speed in some patients. 48 The lack of strong evidence of positive effects should not preclude optimizing spasticity management when trying to improve ambulation in MS, since there have been, to our knowledge, no well-designed published studies carefully evaluating the effect of antispasticity interventions on gait in MS and demonstrating a lack of efficacy.
Furthermore, interventions on spasticity have been shown to improve ambulation in other neurological conditions such as spastic hemiparesis due to stroke.
Fampridine (4-aminopyridine or 4-AP)
Fampridine is a potassium channel blocker. The presumed mechanism of action of fampridine is a facilitation of signal conduction along These are necessary steps to allow PwMS to benefit fully from technological advances in an economic environment in which the costeffectiveness of these technologies will be increasingly scrutinized. Also, we should always remember that ambulation, while of great importance and value, is only one component of mobility. 
